Revenue ($USD) : $12,339,000,000
R&D spend : Not Available
Employees : 25,000
Fiscal year end : 12/31/2023
CEO : Stanley Bergman

www.henryschein.com

Henry Schein’s stock is down more than 10% in 2024 as the major healthcare products and services distributor continues to manage the fallout from last year’s cyberattack. According to filings with the U.S. Securities and Exchange Commission, the company has paid $19 million for remediation efforts alone: $11 million in 2023 and $8 million during the first six months of 2024. The company said in its second-quarter filing with the SEC that residual effects of the cyberattack included decreased sales to episodic customers. The company has operations in 33 countries, with products and services sold to more than 1 million dental practices, laboratories, physician practices, ambulatory surgery centers, and more. Other major news included Henry Schein’s purchase earlier in 2024 of a majority stake in Santa Clarita, California–based TriMed, a manufacturer of orthopedic devices for the lower extremities (foot and ankle) and upper extremities (hand and wrist). –CN

MORE ON MDO: Henry Schein’s cyberattack offers lessons for others